DE69712085T2 - Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle - Google Patents

Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle

Info

Publication number
DE69712085T2
DE69712085T2 DE69712085T DE69712085T DE69712085T2 DE 69712085 T2 DE69712085 T2 DE 69712085T2 DE 69712085 T DE69712085 T DE 69712085T DE 69712085 T DE69712085 T DE 69712085T DE 69712085 T2 DE69712085 T2 DE 69712085T2
Authority
DE
Germany
Prior art keywords
hepatitis
complex
ns4a
virus
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69712085T
Other languages
English (en)
Other versions
DE69712085D1 (de
Inventor
L Kim
A Morgenstern
Chao Lin
Ted Fox
A Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69712085D1 publication Critical patent/DE69712085D1/de
Publication of DE69712085T2 publication Critical patent/DE69712085T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30Drug targeting using structural data; Docking or binding prediction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69712085T 1996-09-12 1997-09-12 Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle Expired - Lifetime DE69712085T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
PCT/US1997/016182 WO1998011134A1 (en) 1996-09-12 1997-09-12 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained

Publications (2)

Publication Number Publication Date
DE69712085D1 DE69712085D1 (de) 2002-05-23
DE69712085T2 true DE69712085T2 (de) 2002-11-28

Family

ID=26699520

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69723485T Expired - Lifetime DE69723485T2 (de) 1996-09-12 1997-09-12 Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
DE69736995T Expired - Lifetime DE69736995T2 (de) 1996-09-12 1997-09-12 Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
DE69712085T Expired - Lifetime DE69712085T2 (de) 1996-09-12 1997-09-12 Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69723485T Expired - Lifetime DE69723485T2 (de) 1996-09-12 1997-09-12 Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
DE69736995T Expired - Lifetime DE69736995T2 (de) 1996-09-12 1997-09-12 Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle

Country Status (13)

Country Link
US (2) US6153579A (de)
EP (1) EP0935609B1 (de)
JP (1) JP2001501602A (de)
AT (3) ATE346088T1 (de)
AU (1) AU736857B2 (de)
CA (1) CA2264964A1 (de)
DE (3) DE69723485T2 (de)
DK (1) DK0935609T3 (de)
ES (2) ES2175462T3 (de)
HK (2) HK1022700A1 (de)
IL (1) IL128826A0 (de)
PT (2) PT935609E (de)
WO (1) WO1998011134A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
WO2000040707A1 (en) 1999-01-08 2000-07-13 Bristol-Myers Squibb Co. Modified forms of hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2002217838A1 (en) 2000-11-14 2002-05-27 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells LSI-01
WO2002088303A2 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1951748B1 (de) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Varianten des hepatitis-c-virus
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1991229A2 (de) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Kokristalle und pharmazeutische zusammensetzungen damit
CA2646229A1 (en) * 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
AP2009004960A0 (en) 2007-02-27 2009-08-31 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
EP2436682A1 (de) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Kokristalle und pharmazeutische Zusammensetzungen damit
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
HK1022700A1 (en) 2000-08-18
IL128826A0 (en) 2000-01-31
DE69723485D1 (de) 2003-08-14
PT935609E (pt) 2002-09-30
US6153579A (en) 2000-11-28
US6303287B1 (en) 2001-10-16
DE69723485T2 (de) 2004-05-27
DE69736995D1 (de) 2007-01-04
DE69712085D1 (de) 2002-05-23
AU736857B2 (en) 2001-08-02
JP2001501602A (ja) 2001-02-06
CA2264964A1 (en) 1998-03-19
ATE244729T1 (de) 2003-07-15
DE69736995T2 (de) 2007-09-20
WO1998011134A1 (en) 1998-03-19
ATE346088T1 (de) 2006-12-15
DK0935609T3 (da) 2002-07-22
ES2202228T3 (es) 2004-04-01
AU4414597A (en) 1998-04-02
EP0935609B1 (de) 2002-04-17
ES2175462T3 (es) 2002-11-16
EP0935609A1 (de) 1999-08-18
PT1118619E (pt) 2003-11-28
HK1038573A1 (en) 2002-03-22
ATE216400T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
DE69712085D1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
BG103392A (en) Serine protease inhibitors, in particular of hepatitis with virus ns3 protease
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
DE59410380D1 (de) Endosomolytisch wirksame partikel
ATE500323T1 (de) Subtilisin-variante
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
DE69433240D1 (de) Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ES2165269A1 (es) Derivados de alfa-cetoamidas.
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
ATE195124T1 (de) Kondensierte pyrrolo(2,3-c) carbazole-6-one die die aktivität von gamma interferon potenzieren
DE68927379D1 (de) Plättchen blockierende peptide
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
DE69131253D1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
FI923020A (fi) Inte a inte b-sekvenser.
NO20015398D0 (no) Endoparasitticidisk synergistisk kombinasjon inneholdende cykliske depsipeptider og piperaziner
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
IT1270941B (it) Peptidi di hcv e loro usi.
RU97111590A (ru) Средство для лечения хронического простатита

Legal Events

Date Code Title Description
8364 No opposition during term of opposition